Literature DB >> 32066256

Effects of Bifidobacterium animalis subsp. lactis HN019 on ligature-induced periodontitis in rats with experimental rheumatoid arthritis.

R S Cardoso1, M R Messora1, P H F Silva1, L F Oliveira1, C Leite-Panissi2, S Salvador3, R Casarin4, A B Novaes1, D B Palioto1, F A C Furlaneto1.   

Abstract

The purpose of this study was to evaluate the effects of systemic administration of the probiotic Bifidobacterium animalis subsp. lactis HN019 (HN019) on ligature-induced periodontitis in rats with experimental rheumatoid arthritis (RA). 28 rats were divided into four groups (n=7): RA (rheumatoid arthritis), RA/PROB (probiotic), RA/EP (experimental periodontitis) and RA/EP/PROB. From day zero, HN019 was added daily to the water of the PROB groups animals until the end of the experiment. From day seven, RA was induced. On day 28, in EP groups, ligatures were positioned around mandibular first molars and remained in position for 11 days, in order to induce periodontitis. The animals were euthanised on day 39. Microtomographic, histomorphometric, immunoenzymatic and microbiological analyses were performed. Data were statistically analysed (P<0.05). Group RA/EP/PROB presented reduced alveolar bone loss, tumour necrosis factor-α and interleukin (IL)-6 levels and increased IL-17 levels when compared with group RA/EP. There were no significant differences regarding connective tissue attachment level and IL-10 levels between groups RA/EP and RA/EP/PROB. Group RA/PROB showed decreased anti-citrullinated protein antibodies levels when compared with groups RA and RA/EP. Group RA/EP/PROB presented a higher rate of aerobic/anaerobic bacteria than group RA/EP. Systemic administration of HN019 promoted a protective effect against periodontal tissue destruction, decreasing both bone loss and inflammatory mediators and increasing the proportion of bacteria compatible with periodontal health, in rats with experimental RA and EP.

Entities:  

Keywords:  bone resorption; periodontal disease; probiotics; rheumatic diseases

Year:  2019        PMID: 32066256     DOI: 10.3920/BM2019.0038

Source DB:  PubMed          Journal:  Benef Microbes        ISSN: 1876-2883            Impact factor:   4.205


  5 in total

1.  Lactobacillus reuteri AN417 cell-free culture supernatant as a novel antibacterial agent targeting oral pathogenic bacteria.

Authors:  Kyung Mi Yang; Ji-Sun Kim; Hye-Sung Kim; Young-Youn Kim; Jeong-Kyu Oh; Hye-Won Jung; Doo-Sang Park; Kwang-Hak Bae
Journal:  Sci Rep       Date:  2021-01-15       Impact factor: 4.379

2.  Analysis of gut microbiota and metabolites in patients with rheumatoid arthritis and identification of potential biomarkers.

Authors:  Yumei Chen; Chiyu Ma; Lixiong Liu; Jingquan He; Chengxin Zhu; Fengping Zheng; Weier Dai; Xiaoping Hong; Dongzhou Liu; Donge Tang; Yong Dai
Journal:  Aging (Albany NY)       Date:  2021-10-20       Impact factor: 5.682

Review 3.  Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies.

Authors:  Angelica Leticia Reis Pavanelli; Bruna Silva de Menezes; Erica Bianca Barbosa Pereira; Fabio Assuncao de Souza Morais; Joni Augusto Cirelli; Rafael Scaf de Molon
Journal:  Biomed Res Int       Date:  2022-05-02       Impact factor: 3.246

Review 4.  Use of the Probiotic Bifidobacterium animalis subsp. lactis HN019 in Oral Diseases.

Authors:  Lisa Danielly Curcino Araujo; Flávia Aparecida Chaves Furlaneto; Léa Assed Bezerra da Silva; Yvonne L Kapila
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

Review 5.  Intestinal Dysbiosis in, and Enteral Bacterial Therapies for, Systemic Autoimmune Diseases.

Authors:  Eric Marietta; Ashutosh K Mangalam; Veena Taneja; Joseph A Murray
Journal:  Front Immunol       Date:  2020-10-28       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.